TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06531863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin is a bioactive compound found in turmeric (Curcuma longa), known for its potent anti-inflammatory, antioxidant, and antimicrobial properties. Its therapeutic effects are primarily attributed to its ability to modulate various molecular targets and signaling pathways within the body

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin Gallate
Description: Epigallocatechin gallate (EGCG) is a type of catechin, a natural phenol, and antioxidant found predominantly in green tea. EGCG is known for its potent health-promoting properties, including strong antioxidant, anti-inflammatory, and anti-carcinogenic effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be consumed after randomization.
Study: NCT05957068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care group.
Study: NCT06087172

Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minutes Stepper Test (6MST)
Description: Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
Study: NCT05294107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional biopsies
Description: After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: additional biopsies
Description: After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional biopsies
Description: After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.
Study: NCT04460872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Subjects receive testosterone (100 mg/week) by intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Subjects receive testosterone (100 mg/week) by intramuscular injection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Subjects receive locomotor training (4 sessions/week for 2-3 months)
Study: NCT04737642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Papillary ballon dilatation
Description: Trans cystic papillary ballon dilatation during cholecystectomy
Study: NCT04102475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eatline
Description: After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition
Study: NCT04787939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Feeding
Description: Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
Study: NCT05475184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-547
Description: Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal.
Study: NCT05973838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Delivered Behavioral Activation (Peer Activate)
Description: The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention.
Study: NCT06323642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic containing Lactobacillus rhamnosus GG.
Description: probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: milk as placebo
Study: NCT06431828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP
Description: The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
Study: NCT05035017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Lens
Description: Daily disposable with modified lens design for 2 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Daily disposable with modified lens design for 2 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Daily disposable lens for 2 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: Daily disposable lens for 2 days
Study: NCT04765501

Intervention type: OTHER
Intervention: Survey study
Description: Headache Impact Questionnaire (HIQ) will be applied.
Study: NCT04574947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine
Description: Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous placebo
Description: During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous placebo
Description: During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-cuff lidocaine
Description: The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-cuff placebo
Description: The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intra-cuff placebo
Description: The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
Study: NCT06011499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Exercise Intervention
Description: Participate in online supervised, group resistance training sessions (iLIVE)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Diet Intervention
Description: Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Intervention
Description: Receive usual care receiving educational information about diet and exercise for cancer survivors
Study: NCT06326723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: 25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: 25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.).
Study: NCT05225961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
Study: NCT04688164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT06251076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.
Study: NCT05621564

Intervention type: DRUG
Intervention: pre-operative therapy
Description: pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy

Intervention type: DRUG
Intervention: pre-operative therapy
Description: pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
Study: NCT05594342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 7.5Mg Tab
Description: Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOBUTamine Injectable Solution
Description: Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOBUTamine Injectable Solution
Description: Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
Study: NCT05092659

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient interview
Description: Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
Study: NCT06282250

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy
Description: Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy
Description: Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psycho-education + Imagery focused Cognitive Therapy
Description: Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions.
Study: NCT05585216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma
Description: intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
Study: NCT05066620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal medicine FYTF-919
Description: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine FYTF-919
Description: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
Study: NCT05117944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drama-supported patient role experience
Description: The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
Study: NCT06224504

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine health education
Description: guided the diet of patients, and introduced the knowledge of the disease in detail

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine health education
Description: guided the diet of patients, and introduced the knowledge of the disease in detail